WallStreetZenWallStreetZen

NASDAQ: MTEM
Molecular Templates Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MTEM stock forecasts and price targets.

Forecast return on equity

Is MTEM forecast to generate an efficient return?
Company
-97.22%
Industry
-748.45%
Market
49.39%
MTEM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MTEM forecast to generate an efficient return on assets?
Company
-25.89%
Industry
26.75%
MTEM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MTEM earnings per share forecast

What is MTEM's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$2.70-629.41%
Avg 2 year Forecast
-$2.85-658.82%
Avg 3 year Forecast
-$2.40-570.59%

MTEM revenue growth forecast

How is MTEM forecast to perform vs Biotechnology companies and vs the US market?
Company
-30.82%
Industry
35.42%
Market
9.66%
MTEM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MTEM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MTEM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MTEM$1.44N/AN/A
BIVI$1.20$30.00+2,400.00%Strong Buy
CDT$0.10N/AN/A
IKT$1.25$15.00+1,100.00%Buy
RNAZ$0.54$3.00+455.56%Buy
View Top Biotech Stocks

Molecular Templates Stock Forecast FAQ

What is MTEM's earnings growth forecast for 2024-2026?

(NASDAQ: MTEM) Molecular Templates's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.77%.

Molecular Templates's earnings in 2024 is -$15,626,000.On average, 1 Wall Street analyst forecast MTEM's earnings for 2024 to be -$17,776,476, with the lowest MTEM earnings forecast at -$17,776,476, and the highest MTEM earnings forecast at -$17,776,476. On average, 1 Wall Street analyst forecast MTEM's earnings for 2025 to be -$18,764,058, with the lowest MTEM earnings forecast at -$18,764,058, and the highest MTEM earnings forecast at -$18,764,058.

In 2026, MTEM is forecast to generate -$15,801,312 in earnings, with the lowest earnings forecast at -$15,801,312 and the highest earnings forecast at -$15,801,312.

If you're new to stock investing, here's how to buy Molecular Templates stock.

What is MTEM's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MTEM) forecast ROE is -97.22%, which is considered weak.

What is MTEM's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: MTEM) Molecular Templates's current Earnings Per Share (EPS) is $0.51. On average, analysts forecast that MTEM's EPS will be -$2.70 for 2024, with the lowest EPS forecast at -$2.70, and the highest EPS forecast at -$2.70. On average, analysts forecast that MTEM's EPS will be -$2.85 for 2025, with the lowest EPS forecast at -$2.85, and the highest EPS forecast at -$2.85. In 2026, MTEM's EPS is forecast to hit -$2.40 (min: -$2.40, max: -$2.40).

What is MTEM's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MTEM) forecast ROA is -25.89%, which is lower than the forecast US Biotechnology industry average of 26.75%.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.